Thomas W. Hare has been appointed vice president, Clinical Operations at Advaxis, Inc. Mr. Hare has more than 28 years of experience in the biopharmaceutical and CROs industries overseeing the management of global commercial and clinical operations, data management, outsourcing and medical writing groups.
 
Mr. Hare will oversee clinical operations for the company’s multiple Lm-LLO cancer immunotherapy clinical programs, and will report to Advaxis’s executive vice president, chief medical officer, David J. Mauro, MD, Ph.D.
 
Advaxis has initiated three new clinical trials, including the combination study involving ADXS-PSA and Merck’s PD-1 checkpoint inhibitor KEYTRUDA (pembrolizumab). The company also expects to initiate five additional clinical trials by the end of year to evaluate its Lm-LLO immunotherapy platform.
 
Most recently, Mr. Hare served as vice president, Drug Development Operations for Incyte Corp. He joined Incyte in 2004 and was responsible for the strategic growth and development of a team, which planned, implemented Phase I through Phase III multinational clinical trials in cancer immunotherapy and cancer inflammation clinical trials.
 
Prior to Incyte, Mr. Hare was director of operations at PRA International and served as vice president, Clinical Operations Division for Premier Research and as clinical manager/senior clinical scientist for Bristol Myers-Squibb.
 
“Adding an individual of Thomas’s expertise comes at a pivotal moment for Advaxis as we continue to advance several clinical programs during 2015, including the initiation of five new clinical trials,” said Daniel J. O’Connor, president and chief executive officer of Advaxis. “Thomas brings a wealth of experience overseeing the design, conduct and management of resources for clinical trials. His expertise will be essential as we look to expand our clinical development program, while ensuring we remain on budget and on track.”